<DOC>
	<DOCNO>NCT00891020</DOCNO>
	<brief_summary>This 3 arm randomize open label study evaluate safety , tolerability efficacy tocilizumab patient moderate severe active rheumatoid arthritis , inadequate response unable tolerate DMARDs . The protocol incorporate risk mitigation strategy develop partnership FDA manage know potential risk associate treatment tocilizumab . Patients randomize receive tocilizumab either 4 mg/kg intravenous ( iv ) 8 mg/kg iv concomitant non-biologic DMARDs , 8 mg/kg iv without concomitant non-biologic DMARDs , every 4 week , total 6 infusion . The anticipated time study treatment 3-12 month , target sample size 500-1000 individual .</brief_summary>
	<brief_title>A Study Of Tocilizumab Patients With Moderate Severe Active Rheumatoid Arthritis Who Have Inadequate Response Are Unable Tolerate Biologic Non-Biologic Disease-modifying Antirheumatic Drugs ( DMARDs )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; moderate severe active rheumatoid arthritis &gt; 6 month ; inadequate clinical response unable tolerate current prior biologic nonbiologic Diseasemodifying antirheumatic drug ( DMARD ) therapy ; Swollen joint count ( SJC ) &gt; /=4 Tender joint count ( TJC ) &gt; /=4 body weight &lt; /=150kg current permit nonbiologic DMARDs must stable dose &gt; /= 7 week prior baseline ; history autoimmune disease inflammatory joint disease rheumatoid arthritis ; functional class IV define American College Rheumatology ( ACR ) Classification Functional Status rheumatoid arthritis ; treatment rituximab within 6 month screen ; intraarticular corticosteroid within 8 week intramuscular ( im ) / intravenous ( iv ) corticosteroid within 12 week prior screen ; know active current history recurrent infection , major episode infection require hospitalization treatment iv antibiotic within 4 week screen , oral antibiotic within 2 week prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>